United States — Food and Drug Administration & Danielle Peyton

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a Complete Response Letter to Aldeyra Therapeutics, citing a lack of substantial evidence for the efficacy of reproxalap, which triggered the stock price drop and subsequent lawsuits.

Danielle Peyton: Danielle Peyton is associated with Pomerantz LLP and is a contact for investors interested in joining the class action lawsuit against Aldeyra Therapeutics.

United States — Food and Drug Administration: The United States — Food and Drug Administration's delayed clearance for Caris Life Sciences' TriNav Advance product is a key factor contributing to the company's financial issues and the subsequent investor investigations.

Danielle Peyton: Danielle Peyton is the contact person at Pomerantz LLP for investors interested in joining the investigation against Caris Life Sciences Inc.

United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body that Oculis will not pursue a filing with for its drug candidate OCS-01, following the failed clinical trials.

Danielle Peyton: Danielle Peyton is a contact person at Pomerantz LLP for investors interested in joining the investigation against Oculis.

United States — Food and Drug Administration: The United States — Food and Drug Administration placed a full clinical hold on MiNK Therapeutics' investigational new drug application for ARD-101, directly impacting the company's drug development and stock performance.

Danielle Peyton: Danielle Peyton is the contact person at Pomerantz LLP for investors interested in joining the class action against MiNK Therapeutics.

United States — Food and Drug Administration: The FDA approved Celcuity's therapy, but the approval was expected; the delay in launch is the issue.

Danielle Peyton: Danielle Peyton is the contact at Pomerantz LLP for the investigation.